Citations

Clear

479 citation(s) found for "Tobias, JS".

Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk Stratification
Escalante, Patricio , Peikert, Tobias, Keulen, Virginia P. Van , Erskine, Courtney L. , Bornhorst, Cathy L., Andrist, Boleyn R., McCoy, Kevin , Pease, Larry R. , Abraham, Roshini S. , Knutson, Keith L. , Kita, Hirohito , Schrum, Adam G. , Knutson, Keith L. , Limper, Andrew H. , Kita, H , Schrum, Adam G

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 1, 2015 | Volume: 192 | Issue: 5 | Pages: 605-617

10.1164/rccm.201412-2141oc | PMID 26030344 Get It

Abstract Rationale Most immunocompetent patients diagnosed with latent tuberculosis infection (LTBI) will not progress to tuberculosis (TB) reactivation. However, current diagnostic tools cannot reliably distinguish nonprogressing from progressing patients a priori, and thus LTBI therapy must be prescribed with suboptimal patient specificity. We hypothesized that LTBI diagnostics could be improved by generating immunomarker profiles capable of categorizing distinct patient subsets by a combinatorial immunoassay approach. Objectives A combinatorial immunoassay analysis was applied to identify potential immunomarker combinations that distinguish among unexposed subjects, untreated patients with LTBI, and treated patients with LTBI and to differentiate risk of reactivation. Methods IFN-γ release assay (IGRA) was combined with a flow cytometric assay that detects induction of CD25+CD134+ coexpression on TB antigen–stimulated T cells from peripheral blood. The combinatorial immunoassay analysis was based on receiver operating characteristic curves, technical cut-offs, 95% bivariate normal density ellipse prediction, and statistical analysis. Risk of reactivation was estimated with a prediction formula. Measurements and Main Results Sixty-five out of 150 subjects were included. The combinatorial immunoassay approach identified at least four different T-cell subsets. The representation of these immune phenotypes was more heterogeneous in untreated patients with LTBI than in treated patients with LTBI or unexposed groups. Patients with IGRA(+) CD4+CD25+CD134+ T-cell phenotypes had the highest estimated reactivation risk (4.11 ± 2.11%). Conclusions These findings suggest that immune phenotypes defined by combinatorial assays may potentially have a role in identifying those at risk of developing TB; this potential role is supported by risk of reactivation modeling. Prospective studies will be needed to test this novel approach.
Migraine and the vascular system: Much has been learned but still a long way to go
Kurth, Tobias , Dodick, David W. , Kurth, Tobias

Mayo Clinic

Cephalalgia | January 22, 2015 | Volume: 35 | Issue: 2 | Pages: 83-84

10.1177/0333102414566050 | PMID 25613014 Get It

The Immunoregulator Soluble TACI Is Released by ADAM10 and Reflects B Cell Activation in Autoimmunity
Kuhn, Peer‐Hendrik , Laurent, Sarah , Hauck, Stefanie M. , Berer, Kerstin, Wendlinger, Simone A., Krumbholz, Markus , Khademi, Mohsen , Olsson, Tomas , Dreyling, Martin , Pfister, H.-W., Alexander, Tobias , Hiepe, Falk , Kümpfel, Tania , Wekerle, Hartmut , Hohlfeld, Reinhard , Meinl, Edgar , Crawford, Howard C, Hoffmann, Franziska S. , Crawford, Howard C. , Lichtenthaler, Stefan F.

Mayo Clinic

The Journal of Immunology | December 11, 2014 | Volume: 194 | Issue: 2 | Pages: 542-552

10.4049/jimmunol.1402070 | PMID 25505277 Get It

Abstract BAFF and a proliferation-inducing ligand (APRIL), which control B cell homeostasis, are therapeutic targets in autoimmune diseases. TACI-Fc (atacicept), a soluble fusion protein containing the extracellular domain of the BAFF–APRIL receptor TACI, was applied in clinical trials. However, disease activity in multiple sclerosis unexpectedly increased, whereas in systemic lupus erythematosus, atacicept was beneficial. In this study, we show that an endogenous soluble TACI (sTACI) exists in vivo. TACI proteolysis involved shedding by a disintegrin and metalloproteinase 10 releasing sTACI from activated B cells. The membrane-bound stub was subsequently cleaved by γ-secretase reducing ligand-independent signaling of the remaining C-terminal fragment. The shed ectodomain assembled ligand independently in a homotypic way. It functioned as a decoy receptor inhibiting BAFF- and APRIL-mediated B cell survival and NF-κB activation. We determined sTACI levels in autoimmune diseases with established hyperactivation of the BAFF–APRIL system. sTACI levels were elevated both in the cerebrospinal fluid of the brain-restricted autoimmune disease multiple sclerosis correlating with intrathecal IgG production, as well as in the serum of the systemic autoimmune disease systemic lupus erythematosus correlating with disease activity. Together, we show that TACI is sequentially processed by a disintegrin and metalloproteinase 10 and γ-secretase. The released sTACI is an immunoregulator that shares decoy functions with atacicept. It reflects systemic and compartmentalized B cell accumulation and activation.
Significant muscle damage after multiple revision total hip replacements through the direct lateral approach
Roth, Philipp von , Wauer, F., Winkler, Tobias , Wassilew, Georgi I. , Diederichs, Gerd, Perka, Carsten , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | December 1, 2014 | Volume: 96-B | Issue: 12 | Pages: 1618-1622

10.1302/0301-620x.96b12.34256 | PMID 25452363 Get It

Intact abductors of the hip play a crucial role in preventing limping and are known to be damaged through the direct lateral approach. The extent of trauma to the abductors after revision total hip replacement (THR) is unknown. The aim of this prospective study was to compare the pre- and post-operative status of the gluteus medius muscle after revision THR. We prospectively compared changes in the muscle and limping in 30 patients who were awaiting aseptic revision THR and 15 patients undergoing primary THR. The direct lateral approach as described by Hardinge was used for all patients. MRI scans of the gluteus medius and functional analyses were recorded pre-operatively and six months post-operatively. The overall mean fatty degeneration of the gluteus medius increased from 35.8% (1.1 to 98.8) pre-operatively to 41% (1.5 to 99.8) after multiple revision THRs (p = 0.03). There was a similar pattern after primary THR, but with considerably less muscle damage (p = 0.001), indicating progressive muscle damage. Despite an increased incidence of a positive Trendelenburg sign following revision surgery (p = 0.03) there was no relationship between the cumulative fatty degeneration in the gluteus medius and a positive Trendelenburg sign (p = 0.26). The changes associated with other surgical approaches to the hip warrant investigation. Cite this article: Bone Joint J 2014;96-B:1618–22.
Gender-specific Research for Emergency Diagnosis and Management of Ischemic Heart Disease: Proceedings from the 2014Academic Emergency MedicineConsensus Conference Cardiovascular Research Workgroup
Safdar, Basmah , Nagurney, John Tobias , Anise, Ayodola , DeVon, Holli A. , D’Onofrio, Gail , Hollander, Judd E. , Legato, Mariane J., McGregor, Alyson J. , Scott, Jane D, Tewelde, Semhar Z., Diercks, Deborah B. , Hess, Erik P.

Mayo Clinic

Academic Emergency Medicine | November 20, 2014 | Volume: 21 | Issue: 12 | Pages: 1350-1360

10.1111/acem.12527 | PMID 25413468 Get It

Identification of Independent Primary Tumors and Intrapulmonary Metastases Using DNA Rearrangements in Non–Small-Cell Lung Cancer
Aubry, Marie-Christine, Harris, Faye R. , Halling, Geoffrey C. , Johnson, Sarah H. , Terra, Simone , Drucker, Travis, Kipp, Benjamin R. , Yi, Eunhee S. , Peikert, Tobias, Vasmatzis, George , Wigle, Dennis A. , Drucker, Travis M, Asiedu, Michael K. , Murphy, Stephen J. , Yang, Ping

Mayo Clinic

Journal of Clinical Oncology | November 11, 2014 | Volume: 32 | Issue: 36 | Pages: 4050-4058

10.1200/jco.2014.56.7644 | PMID 25385739 Get It

Purpose Distinguishing independent primary tumors from intrapulmonary metastases in non–small-cell carcinoma remains a clinical dilemma with significant clinical implications. Using next-generation DNA sequencing, we developed a chromosomal rearrangement–based approach to differentiate multiple primary tumors from metastasis. Methods Tumor specimens from patients with known independent primary tumors and metastatic lesions were used for lineage test development, which was then applied to multifocal tumors. Laser capture microdissection was performed separately for each tumor. Genomic DNA was isolated using direct in situ whole-genome amplification methodology, and next-generation sequencing was performed using an Illumina mate-pair library protocol. Sequence reads were mapped to the human genome, and primers spanning the fusion junctions were used for validation polymerase chain reaction. Results A total of 41 tumor samples were sequenced (33 adenocarcinomas [ADs] and eight squamous cell carcinomas [SQCCs]), with a range of three to 276 breakpoints per tumor identified. Lung tumors predicted to be independent primary tumors based on different histologic subtype did not share any genomic rearrangements. In patients with lung primary tumors and paired distant metastases, shared rearrangements were identified in all tumor pairs, emphasizing the patient specificity of identified breakpoints. Multifocal AD and SQCC samples were reviewed independently by two pulmonary pathologists. Concordance between histology and genomic data occurred in the majority of samples. Discrepant tumor samples were resolved by genome sequencing. Conclusion A diagnostic lineage test based on genomic rearrangements from mate-pair sequencing demonstrates promise for distinguishing independent primary from metastatic disease in lung cancer.
Targeting B Lymphocytes in Progressive Fibrosing Mediastinitis
Westerly, Blair, Johnson, Geoffrey B. , Maldonado, Fabien , Utz, James P., Peikert, Tobias, Johnson, Geoffrey B. , Westerly, Blair D, Specks, Ulrich , Johnson, Geoffrey B , Johnson, Geoffrey B

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | October 31, 2014 | Volume: 190 | Issue: 9 | Pages: 1069-1071

10.1164/rccm.201407-1258le | PMID 25360730 Get It

Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Miloslavsky, Eli M. , Seo, Philip , Langford, Carol A. , Hoffman, Gary S., Kallenberg, Cees G. M., Clair, E. William St. , Tchao, Nadia K., Viviano, Lisa, Ding, Linna , Iklé, David , Villarreal, Miguel, Jepson, Brett , Brunetta, P., Allen, Nancy B., Keogh, Karina A., Peikert, Tobias, Stegeman, Coen A. , Ytterberg, Steven R. , Stone, John H., Brunetta, Paul , Specks, Ulrich , Merkel, Peter A. , Spiera, Robert , Fervenza, Fernando C. , Geetha, Duvuru , Kissin, Eugene Y. , Monach, Paul A.

Mayo Clinic

Arthritis & Rheumatology | July 21, 2014 | Volume: 66 | Issue: 11 | Pages: 3151-3159

10.1002/art.38788 | PMID 25047592 Get It

ObjectiveDisease relapses are frequent in antineutrophil cytoplasmic antibody–associated vasculitis (AAV). This study was undertaken to evaluate outcomes in patients with AAV who are re‐treated with rituximab (RTX) and prednisone for severe disease relapses.MethodsThe Rituximab in AAV trial was a randomized, double‐blind, placebo‐controlled trial comparing the rates of remission induction among patients treated with RTX (n = 99) and patients treated with cyclophosphamide (CYC) followed by azathioprine (AZA) (n = 98). Prednisone was tapered to discontinuation after 5.5 months. After remission was achieved, patients who experienced a severe disease relapse between months 6 and 18 were eligible to receive RTX and prednisone on an open‐label basis according to a prespecified protocol. Investigators remained blinded with regard to the original treatment assignment.ResultsTwenty‐six patients received RTX for disease relapse after remission had initially been achieved with their originally assigned treatment. Fifteen of these patients were initially randomized to receive RTX and 11 to receive CYC/AZA. Thirteen (87%) of the patients originally assigned to receive RTX and 10 (91%) originally assigned to receive CYC/AZA achieved remission again with open‐label RTX (an overall percentage of 88%). In half of the patients treated with open‐label RTX, prednisone could be discontinued entirely. Patients in this cohort experienced fewer adverse events compared to the overall study population (4.7 adverse events per patient‐year versus 11.8 adverse events per patient‐year).ConclusionRe‐treatment of AAV relapses with RTX and glucocorticoids appears to be a safe and effective strategy, regardless of previous treatment.
Genomic Rearrangements Define Lineage Relationships between Adjacent Lepidic and Invasive Components in Lung Adenocarcinoma
Wigle, Dennis A. , Lima, Joema Felipe , Harris, Faye R. , Johnson, Sarah H. , Halling, Geoffrey C. , Seto, C, Terra, Simone , Kosari, Farhad , Peikert, Tobias, Aubry, Marie-Christine, Vasmatzis, George , Halling, Geoffrey, Asiedu, Michael K. , Seto, Charlie T, Murphy, Stephen J. , Yang, Ping

Mayo Clinic

Cancer Research | May 30, 2014 | Volume: 74 | Issue: 11 | Pages: 3157-3167

10.1158/0008-5472.can-13-1727 | PMID 24879567 Get It

AbstractThe development of adenocarcinoma of the lung is believed to proceed from in situ disease (adenocarcinoma in situ, AIS) to minimally invasive disease with prominent lepidic growth (minimally invasive adenocarcinoma, MIA), then to fully invasive adenocarcinoma (AD), but direct evidence for this model has been lacking. Because some lung adenocarcinomas show prominent lepidic growth (AD-L), we designed a study to address the lineage relationship between the lepidic (noninvasive) component (L) and the adjacent nonlepidic growth component representing invasive disease within individual tumors. Lineage relationships were evaluated by next-generation DNA sequencing to define large genomic rearrangements in microdissected tissue specimens collected by laser capture. We found a strong lineage relationship between the majority of adjacent lepidic and invasive components, supporting a putative AIS–AD transition. Notably, many rearrangements were detected in the less aggressive lepidic component, although the invasive component exhibited an overall higher rate of genomic rearrangement. Furthermore, a significant number of genomic rearrangements were present in histologically normal lung adjacent to tumor, but not in host germline DNA, suggesting field defects restricted to zonal regions near a tumor. Our results offer a perspective on the genetic pathogenesis underlying adenocarcinoma development and its clinical management. Cancer Res; 74(11); 3157–67. ©2014 AACR.
Primary Antiphospholipid Syndrome–Associated Diffuse Alveolar Hemorrhage
Cartin‐Ceba, Rodrigo , Peikert, Tobias, Ashrani, Aneel A. , Keogh, Karina A., Wylam, Mark E. , Ytterberg, Steven R. , Specks, Ulrich

Mayo Clinic

Arthritis Care & Research | August 27, 2013 | Volume: 66 | Issue: 2 | Pages: 301-310

10.1002/acr.22109 | PMID 23983016 Get It

Objective Diffuse alveolar hemorrhage (DAH) is an uncommon complication of primary antiphospholipid syndrome (APS). We aimed to describe the clinical characteristics, treatment, and outcomes of primary APS–associated DAH in a single center. Methods We conducted a retrospective review of all adults with primary APS–associated DAH evaluated at Mayo Clinic over a 15‐year period. DAH was defined as bilateral pulmonary infiltrates and bronchoalveolar lavage (BAL) fluid documenting progressively bloody returns and/or the presence of >20% hemosiderin‐laden macrophages. Patients with other causes of DAH were excluded. Results Eighteen patients were identified (median age 43 years). Capillaritis was present in surgical lung biopsy samples of 3 patients. BAL differential cell counts revealed predominantly neutrophils. All patients were treated initially with glucocorticoids. Cyclophosphamide (CYC) was used in 8 patients; complete remission was achieved in 3 patients treated with CYC alone and in 1 patient receiving combination therapy with rituximab (RTX). RTX was used in 9 patients; 2 patients achieved remission with RTX alone, whereas 3 patients required combination therapy with CYC or mycophenolate mofetil (MMF). No patient achieved complete remission while receiving single therapy with MMF, azathioprine, or plasma exchange. Intravenous gamma globulin therapy was administered in 5 patients; no patient achieved control of the disease. Six patients died, all because of complications related to uncontrolled DAH or its therapy. Conclusion We present the largest case series of primary APS–associated DAH reported in the literature. DAH carries a very poor prognosis and therapeutic options are limited. Immunosuppression with either CYC or RTX is associated with the highest likelihood of remission induction and should be considered early.